ReviewPaediatric drugs2014
Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
Review in Paediatric drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2025Review
- Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice.Pharmaceuticals (Basel, Switzerland) · 2023Article
- SCMR expert consensus statement for cardiovascular magnetic resonance of acquired and non-structural pediatric heart disease.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2022Review
- The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.Molecules (Basel, Switzerland) · 2022Review
- Juvenile exposure to doxorubicin alters the cardiovascular response to adult-onset psychosocial stress in mice.Stress (Amsterdam, Netherlands) · 2022Article
- The pediatric oncology exercise field speeds up to address important issues regarding chemotherapy-related cardiotoxicity.Frontiers in pediatrics · 2022Article
- Review
- Brazilian Position Statement on the Use Of Multimodality Imaging in Cardio-Oncology - 2021.Arquivos brasileiros de cardiologia · 2021Article
- Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice.FEBS letters · 2021Article
- Pediatric Restrictive Cardiomyopathies.Frontiers in pediatrics · 2021Review
- [Cardiovascular evaluation of patients undergoing cancer treatments at a clinic for childhood cancer survivors in Mexico].Archivos de cardiologia de Mexico · 2020Observational
- Article
- Health Status in Long-Term Survivors of Hepatoblastoma.Cancers · 2019Article
- Use of speckle tracking in the evaluation of late subclinical myocardial damage in survivors of childhood acute leukaemia.The international journal of cardiovascular imaging · 2018Article
- Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.Cardiovascular research · 2018Article
- Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.Journal of the American Heart Association · 2017Article
- Prevention of cardiotoxicity among survivors of childhood cancer.British journal of clinical pharmacology · 2017Review
- The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity.Cardio-oncology (London, England) · 2016Article
- Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.Toxicology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
Abstract
In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.